Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cardiol Therapeutics Inc T.CRDL

Alternate Symbol(s):  CRDL

Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.


TSX:CRDL - Post by User

Bullboard Posts
Comment by Youhillmanon Sep 17, 2020 2:03pm
129 Views
Post# 31577397

RE:Thursday September 17th at 12:30 pm

RE:Thursday September 17th at 12:30 pm

I just took in the Vitual Life Sciences Investor Forum, the presentation was exactly the same as the one on Tuesday at the Wainwright Virtual Conference so nothing new to report.

I did submit a question about Shoppers however Elsley used his full 30 minutes so he didn't address any questions.

With respect to the branding of Cortalex vs. Cardiolrx, not sure the reason for the change in branding name however I think it does speak to issue as to why the product isn't in Shoppers yet.

CRDL explained the delay with Shoppers was due to a Health Canada issue, I'm suggesting it had to do with the regulation on THC less 10 micrograms per gram. CRDL had always stated theirs is less than 5 and had branded Cardiolrx that way. 

However as simple as it sounds I'm guessing CRDL was offside on the regulation because they didn't state less then 10 micrograms per gram.

I'm also guessing that both Cortalex and Cardiolrx are under 5 however they have to comply with the HC regulation in branding, so they are now going with 10 micrograms per gram (slide 30 today showed Cardiolrx < 10 ppm - that's a change from < 5 ppm).

If this is in fact the reason for the delay with Shoppers, I'm even more bullish on CRDL!!
 

Bullboard Posts